Life Sciences Co. Reports Strong Survival Data
Research Report
Therapeutics Company Advances Gene Therapy Breakthrough
Research Report
Biotech Firm Uncovers Breakthrough Gene Therapy in New York
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease
Research Report
Healthcare Tech Firm Finds Big U.S. Opportunity
New Drug for Duchenne Muscular Dystrophy Nears Potential Approval
Research Report
Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy
Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space.Biotech Battles FDA, Target Price Shows Potential 90% Gains
Research Report
Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy. Pharma's Flu Drug Could Be Worth Billions, Analyst Says
Research Report
Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development. Biotech Discovers Breakthrough DMD Therapy Opportunity
Research Report
Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc. Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Research Report
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report. Healthcare Firm Targets Alzheimer's With Technology Breakthrough
Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need.New Remission Data on MG Patients Compelling
Research Report
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report. 
Streetwise Key Charts
